COPENHAGEN, Denmark, April 15 (Bernama-GLOBE NEWSWIRE) -- Arla Foods Ingredients has developed high-protein, nutrient-dense application concepts for users of GLP-1 anti-obesity medications, which it will showcase at Vitafoods Europe (5th-7th May 2026 in Barcelona).
Originally developed to treat diabetes, GLP-1 receptor agonists have re-shaped the weight management market. In 2025, 11% of consumers globally
[1] and 18% in the US
[2] who were actively trying to lose weight reported using them, with uptake expected to rise as availability expands, tablet formats emerge and prices fall
[3].
However, GLP-1 use is associated with side effects: lean muscle loss may reach 40% of total mass lost, versus around 25% with traditional interventions [
4,
5,
6], while up to 76% of GLP-1 consumers report gastric discomfort and reduced appetite
[7].
To help manufacturers address these needs, Arla Foods Ingredients has developed high-protein concepts with Nutrilac® and Lacprodan® BLG-100, delivering all essential amino acids for muscle health in nutrient-dense formats, and incorporating probiotics / cultures from Novonesis to support digestive well-being.
The range includes great-tasting formats for reduced appetites:
Anne Widart, Chief Commercial Officer of Arla Foods Ingredients, said: “Nutrition for GLP-1 users is a growing category, creating opportunities for dairy manufacturers. There is increasing demand for nutrient-dense, high-protein products in formats suited to smaller appetites. Our concepts are designed to help manufacturers respond to these evolving needs.”
Arla Foods Ingredients will showcase the GLP-1 companion nutrition solutions at Vitafoods Europe (Stand #3G156) alongside two additional concepts: